Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 71Cr 62Cr 57Cr 53Cr 100Cr 6.75TCr 100.89Cr 677.18Cr 264.72Cr 3.37TCr 266.43Cr 260.59Cr 11TCr P/E 2026 *
3.64x
P/E 2027 * 3.49x
Enterprise Value 71Cr 62Cr 57Cr 53Cr 100Cr 6.75TCr 100.89Cr 677.18Cr 264.72Cr 3.37TCr 266.43Cr 260.59Cr 11TCr EV / Sales 2026 *
1.54x
EV / Sales 2027 * 1.48x
Free-Float
96.75%
Yield 2026 *
-
Yield 2027 * -
1 day-2.49%
1 week+13.42%
Current month+1.89%
1 month-0.46%
3 months-6.10%
6 months-3.90%
Current year+27.89%
1 week 3.55
Extreme 3.55
4.59
1 month 3.55
Extreme 3.55
4.88
Current year 2.95
Extreme 2.95
5.78
1 year 0.8
Extreme 0.8
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 12/03/2021
Director of Finance/CFO 44 15/05/2026
Chief Tech/Sci/R&D Officer - 20/07/2026
Director TitleAgeSince
Director/Board Member 68 04/06/2021
Chairman 61 01/04/2019
Director/Board Member 56 01/04/2019
Date Insider Type Main position Quantity % Market Cap.
20/07/26 Free

Chief Technology Officer

1,37,036 0.0832%
07/07/26 Sell

Chief Financial Officer

-1,27,890 0.0777%
23/02/26 Sell

Chief Executive Officer

1,98,283 0.1219%
Change 5-day change 1-year change 3-year change Capi.($)
-2.49%+13.42%+474.28%-61.28% 71Cr
+0.18%-2.90%+60.28%+21.90% 32TCr
-1.45%-1.24%+32.81%-10.47% 7.33TCr
+1.17%-0.26%+38.74%+96.25% 987.22Cr
+0.10%-9.19%-4.48%-7.78% 814.85Cr
+1.79%+0.38%-16.96%-17.13% 437.95Cr
+1.63%+5.80%-33.57%+6.86% 391.03Cr
+3.58%+0.05%-16.91%+18.28% 362.48Cr
-5.98%-9.39%+16.73%+34.40% 251.4Cr
-0.82%+6.62%-2.59%-3.15% 224.06Cr
Average -0.22%+0.67%+54.83%+7.79% 4.25TCr
Weighted average by Cap. +0.23%-1.98%+51.58%+16.71%

Financials

2026 *2027 *
Net sales 46Cr 40Cr 37Cr 34Cr 65Cr 4.38TCr 65Cr 439.17Cr 171.68Cr 2.19TCr 172.79Cr 169Cr 7.25TCr 48Cr 42Cr 39Cr 36Cr 67Cr 4.55TCr 68Cr 456.57Cr 178.48Cr 2.27TCr 179.63Cr 175.7Cr 7.54TCr
Net income 18Cr 16Cr 15Cr 14Cr 26Cr 1.73TCr 26Cr 173.33Cr 68Cr 863.51Cr 68Cr 67Cr 2.86TCr 21Cr 18Cr 17Cr 16Cr 30Cr 2TCr 30Cr 200.31Cr 78Cr 997.92Cr 79Cr 77Cr 3.31TCr
Net Debt - -
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
04/26/04 $4.310 -2.49% 57,68,302
03/26/03 $4.420 +4.49% 38,18,188
31/26/31 $4.230 +13.40% 35,83,359
30/26/30 $3.730 +4.78% 12,99,350
29/26/29 $3.560 -6.32% 12,52,812
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.310USD
Average target price
6.350USD
Spread / Average Target
+47.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IRWD Stock